TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28184153

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Malignancy
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Dementia
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF), chronic kidney disease (CKD), and visual impairment
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Hypertension, chronic kidney disease (CKD), and malignancy
Number of subjects: 328
Study: 26520572

Group type: EXPERIMENTAL
Intervention: NAC plus food assistance
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: NAC plus cash transfer
Number of subjects: 788

Group type: COMPARATOR
Intervention: NAC only
Number of subjects: 788
Study: 24937390

Group type: EXPERIMENTAL
Intervention: Double-modality therapy (DMT) - cryotherapy and 15% methyl salicylate phonophoresis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phonophoresis (PHONO) - 15% methyl salicylate phonophoresis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cryotherapy (CRYO) - cryotherapy and 'sham' phonophoresis
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (DMT, PHONO, CRYO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double-modality therapy (DMT)
Number of subjects: 60
Study: 21689019

Group type: EXPERIMENTAL
Intervention: Formoterol by pressurized metered-dose inhaler (pMDI) 12 μg b.i.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Formoterol by dry powder inhaler (DPI) 12 μg b.i.d.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Formoterol by pMDI or DPI
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 18687132

Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant supplements (selenium 270 microg, zinc 30 mg, vitamin C 1.1 g, and vitamin B1 100 mg) for 5 days with a double-loading dose on days 1 and 2
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous antioxidant supplements
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 22238967

Group type: EXPERIMENTAL
Intervention: Annuloplasty of the mitral valve fibrous ring with a synthetic band
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15938902

Group type: EXPERIMENTAL
Intervention: Instrumented posterior fusion (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Instrumented circumferential lumbar fusion (Group B)
Number of subjects: 45
Study: 12631424

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan orally
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9850897

Group type: EXPERIMENTAL
Intervention: 3 drops of lidocaine 4% before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 drops of lidocaine 4% before surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 drops of lidocaine 4% plus intracameral injection of 0.1 mL lidocaine 1%
Number of subjects: 20
Study: 7913157

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1240
Study: 2531908

Group type: EXPERIMENTAL
Intervention: Polyvalent melanoma cell vaccine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyvalent melanoma cell vaccine with low-dose cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other immunomodulators (alone or in combination with lower doses of cyclophosphamide)
Number of subjects: 0
Study: 11711455

Group type: EXPERIMENTAL
Intervention: Intervention trials on treatment of acute myocardial infarction
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Concise verbal information about the study
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Physician decision-making in case of patient incapacity
Number of subjects: 31
Study: 31386987

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 12 sessions
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waiting period (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 65
Study: 29438425

Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization
Number of subjects: 207

Group type: COMPARATOR
Intervention: Topical steroid ointment
Number of subjects: 207
Study: 27328792

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 397

Group type: COMPARATOR
Intervention: Control (conventional imaging)
Number of subjects: 397
Study: 24320943

Group type: EXPERIMENTAL
Intervention: High independence centrality
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Low independence centrality
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Increased disability
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Higher independence centrality at baseline
Number of subjects: 173
Study: 22298017

Group type: EXPERIMENTAL
Intervention: combined intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: parent intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: student intervention
Number of subjects: 3490

Group type: COMPARATOR
Intervention: control group
Number of subjects: 3490
Study: 20150825

Group type: EXPERIMENTAL
Intervention: Cisplatin and pemetrexed (CP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine (CG)
Number of subjects: 126
Study: 17390924

Group type: EXPERIMENTAL
Intervention: Preoperative education and patient education pamphlet, standard nursing care plan and nursing care protocol applied in the postoperative period for Group 2 subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nursing care needs assessment through interviews and observations in Group 1
Number of subjects: 32
Study: 15204669

Group type: EXPERIMENTAL
Intervention: Desipramine with buprenorphine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Desipramine with methadone
Number of subjects: 164

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 164

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo desipramine
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cocaine-free urines
Number of subjects: 164
Study: 11782569

Group type: EXPERIMENTAL
Intervention: Cisapride, 20 mg b.i.d., during 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10095800

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin daily for 6 weeks, followed by 80 mg atorvastatin for another 6 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 41

Group type: COMPARATOR
Intervention: 40 mg simvastatin alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: 40 mg simvastatin with 8-12 g colestyramin
Number of subjects: 41

Group type: COMPARATOR
Intervention: 40 mg simvastatin with 1800 mg nicotinic acid
Number of subjects: 41
Study: 8074019

Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Captopril 6.25 mg
Number of subjects: 117
Study: 2590602

Group type: EXPERIMENTAL
Intervention: 0.025% bromocriptine eye drops
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.25% timolol eye drops
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 4548791

Group type: EXPERIMENTAL
Intervention: Rehabilitative programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29500292

Group type: EXPERIMENTAL
Intervention: Intravenous elamipretide (0.25 mg/kg/h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous elamipretide (highest dose)
Number of subjects: 36
Study: 28774642

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148 (PL‐148)
Number of subjects: 954

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 954
Study: 25551405

Group type: EXPERIMENTAL
Intervention: ST + a‐tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: ST + sham
Number of subjects: 24

Group type: COMPARATOR
Intervention: a‐tDCS
Number of subjects: 24
Study: 24617231

Group type: EXPERIMENTAL
Intervention: Electroacupuncture and manual manipulation (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Simple manual manipulation (group B)
Number of subjects: 160
Study: 21676990

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 10 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical monitoring (no new treatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 80
Study: 17579653

Group type: EXPERIMENTAL
Intervention: Ecoimmunonutrition (EIN) group supplied by Lactobacillus plantarum enteral feeding (n=36)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Parenteral nutrition (PN) group (n=38)
Number of subjects: 76
Study: 17065036

Group type: EXPERIMENTAL
Intervention: Plasma volume expansion (n = 18)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: No plasma volume expansion (n = 19)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal pregnancy controls (n = 29)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Late-onset preeclampsia controls (n = 8)
Number of subjects: 74
Study: 12824815

Group type: EXPERIMENTAL
Intervention: 21‐mg nicotine patch
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 10873077

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma), 200 microg/m2 on days 1, 3, 5, 8, 10, and 12 and i.p. recombinant interleukin 2 (rIL-2), 6.0 x 10(5) IU/m2 (group A) on days 9, 10, and 11
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and rIL-2 plus TILs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and rIL-2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) plus rIL-2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and higher rIL-2 dosing (group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: i.p. recombinant IFN-gamma (rIFN-gamma) and lower rIL-2 dosing (group B)
Number of subjects: 22
Study: 8879704

Group type: EXPERIMENTAL
Intervention: Sodium clodronate, total daily dose of 1600‐3200 mg
Number of subjects: 0
Study: 2000517

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 6229564

Group type: EXPERIMENTAL
Intervention: Trazodone (300 mg mean maintenance dosage, range 200-350 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Imipramine (160 mg mean maintenance dosage, range 150-175 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 26
Study: 31107560

Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine‐and‐prilocaine (LP) cream for 120 minutes
Number of subjects: 0
Study: 30061318

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study: 26848561

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily added to subcutaneous interferon β‐1a therapy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo added to subcutaneous interferon β‐1a therapy
Number of subjects: 304
Study: 24247661

Group type: EXPERIMENTAL
Intervention: Probiotics in cow's milk from birth to 6 months
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cow's milk without probiotics
Number of subjects: 253
Study: 22100490

Group type: EXPERIMENTAL
Intervention: Transrectal radiofrequency hyperthermia (TRFH)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: TRFH with tamsulosin plus clarithromycin
Number of subjects: 159

Group type: COMPARATOR
Intervention: Tamsulosin plus clarithromycin
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: TRFH
Number of subjects: 159
Study: 18974025

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 7 days (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg b.d. and amoxicillin 1g b.d. plus levofloxacin 500 mg o.d. for 10 days (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg b.d. for 7 days (Group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg b.d. for 10 days (Group D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 7 days treatment (Groups A and C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10 days treatment (Groups B and D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Once daily levofloxacin (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Twice daily levofloxacin (Groups C and D)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 160
Study: 17141851

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15854188

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg as needed
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 11980623

Group type: EXPERIMENTAL
Intervention: 5.0 g testosterone gel daily for 10 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2.5 g testosterone gel daily for 10 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5.0 g testosterone gel with washing off after 10 min
Number of subjects: 26
Study: 10635200

Group type: EXPERIMENTAL
Intervention: Ceramic abutments
Number of subjects: 32

Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both abutments
Number of subjects: 32
Study: 7871179

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary stents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibition for CHF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac transplant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pacemakers
Number of subjects: 0
Study: 2032716

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b subcutaneously (s.c.) 5 x 10(6) IU three times weekly for four weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7072623

Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30539771

Group type: EXPERIMENTAL
Intervention: Dynamic prediction using joint modelling
Number of subjects: 304

Group type: COMPARATOR
Intervention: Conventional approach using only baseline predictors
Number of subjects: 304
Study: 27903298

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-protein (HP) meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of TNFα and IL-6 after HC meal
Number of subjects: 18
Study: 24958479

Group type: EXPERIMENTAL
Intervention: Adalimumab (subcutaneous, every 2 weeks for 12 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (subcutaneous, every 2 weeks for 12 weeks)
Number of subjects: 43
Study: 22042703

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.3 mg·kg(‐1)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 178
Study: 20962598

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the affected motor cortex
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation over the unaffected motor cortex
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study: 18299070

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 36743

Group type: COMPARATOR
Intervention: Subconjunctival cefuroxime
Number of subjects: 36743
Study: 15695985

Group type: EXPERIMENTAL
Intervention: Oral mifepristone (200 mg, administered orally)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous oxytocin (infusion)
Number of subjects: 65
Study: 12733689

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 172

Group type: COMPARATOR
Intervention: Droperidol/Dimenhydrinate
Number of subjects: 172
Study: 10761168

Group type: EXPERIMENTAL
Intervention: Fampridine SR (4-aminopyridine)
Number of subjects: 25
Study: 8931223

Group type: EXPERIMENTAL
Intervention: Nondissection method for autogenous vein grafting
Number of subjects: 86
Study: 8507025

Group type: EXPERIMENTAL
Intervention: 4.4 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4.4 mL of 3% prilocaine with 0.03 IU/mL felypressin
Number of subjects: 20
Study: 3908331

Group type: EXPERIMENTAL
Intervention: Acebutolol (100-400 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol (40-160 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study: 3543146

Group type: EXPERIMENTAL
Intervention: Intravenous chloroquine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous chloroquine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral chloroquine
Number of subjects: 60
Study: 28648859

Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus macrolide
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ceftriaxone plus placebo
Number of subjects: 225
Study: 27120107

Group type: EXPERIMENTAL
Intervention: Conventional appendectomy with electro cauterization and silk suture for stump ligation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Appendectomy with LigaSure™ for stump closure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Appendectomy with Harmonic Scalpel™ for stump closure
Number of subjects: 24
Study: 24947924

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 205
Study: 22793957

Group type: EXPERIMENTAL
Intervention: IMF for 2 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: IMF for 4 to 6 weeks
Number of subjects: 2
Study: 20557362

Group type: EXPERIMENTAL
Intervention: PPI-based triple therapy plus S. boulardii for 4 weeks
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: PPI-based triple therapy plus S. boulardii and DA-9601 for 4 weeks
Number of subjects: 991

Group type: COMPARATOR
Intervention: PPI-based 7-day triple therapy
Number of subjects: 991
Study: 18775645

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Olanzapine vs Risperidone
Number of subjects: 1125
Study: 16151466

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) alone (2 x 10 mg/m2/day subcutaneously days 1-14)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony stimulating factor (rhGM-CSF) (150 microg/day s.c. from day 8 to 21)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) plus Interleukin-3 (IL-3) (150 microg/day s.c. from day 8 to 21)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) with GM-CSF or IL-3
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (LD-AraC alone)
Number of subjects: 180
Study: 12483419

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Shunting
Number of subjects: 48

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 48
Study: 10840147

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study: 9370836

Group type: EXPERIMENTAL
Intervention: Fentanyl patient-controlled analgesia
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Morphine patient-controlled analgesia
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Pethidine patient-controlled analgesia
Number of subjects: 254
Study: 1606996

Group type: EXPERIMENTAL
Intervention: Oxazepam 7.5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 35 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 45 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxazepam 50 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3896566

Group type: EXPERIMENTAL
Intervention: Twice daily beclomethasone dipropionate (BDP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Four times daily beclomethasone dipropionate (BDP)
Number of subjects: 36
Study: 30796818

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV dose 1
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29473247

Group type: EXPERIMENTAL
Intervention: D-methionine (100 mg/kg p.o. b.i.d.)
Number of subjects: 60